Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. (Nasdaq: FENC) is a commercial-stage specialty pharmaceutical company focused on reducing cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors. Its product, PEDMARK® (sodium thiosulfate injection), is approved in the United States for patients… From the company’s description.
Over the twelve months to Jun 30, 2026, Fennec Pharmaceuticals Inc. reported revenue of $59.22M, up 77.8% from a year earlier, and a net loss of $3.25M. Its operating margin was −1.9%, and operations used $2.04M in cash. In fiscal 2025, it reported revenue of $44.64M, down 6.1% from fiscal 2024, and a net loss of $9.74M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Fennec Pharmaceuticals Inc. does
In the company’s own words
Fennec Pharmaceuticals Inc. (Nasdaq: FENC) is a commercial-stage specialty pharmaceutical company focused on reducing cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors. Its product, PEDMARK® (sodium thiosulfate injection), is approved in the United States for patients aged one month and older; PEDMARQSI® is the brand name used in Europe, the U.K., Australia and New Zealand. In the United States, Fennec sells PEDMARK® through a field team and provides patient access and reimbursement support through its Fennec HEARS® program. The company licenses commercialization of PEDMARQSI® in Europe, Australia and New Zealand to Norgine, which handles sales and holds the local marketing authorizations, and has a distribution agreement with Inpharmus for Turkey and Gulf Cooperation Council countries. Fennec operates as a virtual drug manufacturer, relying on contract manufacturers and suppliers rather than in-house production. It has no reportable business segments described here; its commercial activities center on PEDMARK® and related licensing and distribution arrangements.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- RESEARCH TRIANGLE PARK, NC
- Fiscal year end
- December
- CIK
- 1211583
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Fennec Pharmaceuticals Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Fennec Pharmaceuticals Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Fennec Pharmaceuticals Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Fennec Pharmaceuticals Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Fennec Pharmaceuticals Inc.'s last four quarterly filings that the numbers alone won't show?”